BioInvent International

BioInvent International is a clinical-stage biotechnology company with a mission to transform cancer treatment through the discovery and development of novel, targeted antibody therapies. The company's strategy is anchored in its proprietary F.I.R.S.T.™ and n-CoDeR® platforms, which enable the identification of biologically relevant targets and the generation of fully human antibodies directly from human tissue. BioInvent has advanced a pipeline of proprietary and partnered candidates, most notably the anti-FcγRIIB antibody BI-1206, positioning itself as a key player in the next wave of immuno-oncology innovation.

The F.I.R.S.T.™ platform identifies novel therapeutic targets from the human tissue secretome, which are then targeted using fully human antibodies from the proprietary n-CoDeR® library, one of the world's largest natural antibody fragment libraries.

BioInvent faces competition from large pharma and biotech firms in the crowded IO field. Its differentiation lies in its proprietary, tissue-centric discovery platforms and focus on novel myeloid targets like FcγRIIB and TNFR2, where it holds first- or early-mover positions.